{"id":976955,"date":"2026-06-30T07:23:53","date_gmt":"2026-06-30T11:23:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/"},"modified":"2026-06-30T07:23:53","modified_gmt":"2026-06-30T11:23:53","slug":"adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/","title":{"rendered":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n 100 r\/r DLBCL patients treated at the selected 150 \u00b5g\/kg dose of ZYNLONTA\u00ae plus glofitamab<\/i>\n <\/p>\n

\n Full data expected in fourth quarter of 2026<\/i>\n <\/p>\n

\n LAUSANNE, Switzerland<\/span>, June 30, 2026<\/span> \/PRNewswire\/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI\u00ae) in patients with relapsed or refractory (r\/r) diffuse large B-cell lymphoma (r\/r DLBCL).<\/p>\n

\n

\n \"ADC\n <\/p>\n<\/p><\/div>\n

LOTIS-7 trial enrollment is now complete with 100 r\/r DLBCL patients dosed at the selected 150 \u00b5g\/kg dose of ZYNLONTA plus glofitamab. Enrollment occurred in 30 total sites with 70% of patients in the US and 30% in the EU. The study enrolled patients with baseline characteristics similar to other bispecific combination studies in this space and included 46% relapsed and 54% primary refractory patients with a median age of 66 years.<\/p>\n

Primary endpoints of the study include safety and tolerability. Secondary endpoints include overall response rate, duration of response, complete response, relapse free survival, progression-free survival, and overall survival, as well as pharmacokinetics and immunogenicity. As part of the study protocol, anti-infective prophylaxis, intravenous\u00a0immunoglobulin (in patients experiencing B-cell loss with an increased risk of infection) and vaccination are strongly recommended.<\/p>\n

“We are excited by the previously reported data from this study which demonstrated an 89.8% ORR and 77.6% CR and a manageable safety profile across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. “We continue to believe this ZYNLONTA combination has the potential to be the best-in-class bispecific antibody-based combination in 2L+ DLBCL. With enrollment now complete, we look forward to sharing more comprehensive results from LOTIS-7 later this year.”<\/p>\n

Further to the previously reported results from LOTIS-7 demonstrating promising clinical activity for the combination of ZYNLONTA plus glofitamab in patients with r\/r DLBCL, the Company plans to share full data from LOTIS-7 at a medical meeting and submit the results for publication by the end of 2026. In addition, the Company plans to assess potential regulatory and compendia pathways for the combination.<\/p>\n

\n About LOTIS-7<\/b>\n <\/p>\n

LOTIS-7 is a Phase 1b global multicenter, multi-arm study in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) including Part 1 (dose escalation) and Part 2 (dose expansion). The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs). Enrollment in LOTIS-7 includes Part 1 of the study with a 3+3 dose escalation in 3L+ heavily pre-treated patients with ZYNLONTA doses starting at 90 \u00b5g\/kg and then proceeding to 120 \u00b5g\/kg and 150 \u00b5g\/kg. Part 2 includes dose expansion in 2L+ large B-cell lymphoma in the ZYNLONTA plus glofitamab arm at dose levels determined from Part 1 (120 \u00b5g\/kg and 150 \u00b5g\/kg of ZYNLONTA plus the approved dosing of glofitamab).<\/p>\n

For more information about the LOTIS-7 trial, visit clinicaltrials.gov<\/a> (NCT04970901).<\/p>\n

\n About ZYNLONTA<\/b>\u00ae<\/p>\n

ZYNLONTA\u00ae is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.<\/p>\n

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r\/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double\/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at www.ZYNLONTA.com<\/a>.<\/p>\n

ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.<\/p>\n

\n About ADC Therapeutics<\/b>\n <\/p>\n

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).<\/p>\n

ADC Therapeutics’ CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.<\/p>\n

Headquartered in Lausanne (Biop\u00f4le), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at https:\/\/adctherapeutics.com\/<\/a> and follow us on LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements<\/b>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether future LOTIS-7 results will be consistent with or different from the prior disclosure, the timing, results and publication of the full LOTIS-7 trial; the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA; the timing, submission and acceptance of an sBLA submission related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions; our ability to identify and execute value-maximizing options and the cost and impact of such options; our expected cash runway into at least 2028; our ability to comply with the terms of our indebtedness; changes in our regulatory and commercial strategy; the Company’s ability to sustain or grow ZYNLONTA\u00ae revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA\u00ae in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA\u00ae in foreign jurisdictions; the timing and results of the Company’s clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and\/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.<\/p>\n

\n CONTACT:<\/b>\n <\/p>\n

\n Investors & Media
<\/b>Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com<\/a>
+1 862-926-9040<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial-302813948.html<\/a><\/p>\n

SOURCE ADC Therapeutics SA<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire 100 r\/r DLBCL patients treated at the selected 150 \u00b5g\/kg dose of ZYNLONTA\u00ae plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 \/PRNewswire\/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI\u00ae) in patients with relapsed or refractory (r\/r) diffuse large B-cell lymphoma (r\/r DLBCL). LOTIS-7 trial enrollment is now complete with 100 r\/r DLBCL patients dosed at the selected 150 \u00b5g\/kg dose of ZYNLONTA plus glofitamab. Enrollment occurred in … <\/p>\n

Continue reading “ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-976955","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire 100 r\/r DLBCL patients treated at the selected 150 \u00b5g\/kg dose of ZYNLONTA\u00ae plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 \/PRNewswire\/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI\u00ae) in patients with relapsed or refractory (r\/r) diffuse large B-cell lymphoma (r\/r DLBCL). LOTIS-7 trial enrollment is now complete with 100 r\/r DLBCL patients dosed at the selected 150 \u00b5g\/kg dose of ZYNLONTA plus glofitamab. Enrollment occurred in … Continue reading "ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T11:23:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1614576\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial\",\"datePublished\":\"2026-06-30T11:23:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\"},\"wordCount\":1543,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1614576\\\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\",\"name\":\"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1614576\\\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688\",\"datePublished\":\"2026-06-30T11:23:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1614576\\\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1614576\\\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/","og_locale":"en_US","og_type":"article","og_title":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Market Newsdesk","og_description":"PR Newswire 100 r\/r DLBCL patients treated at the selected 150 \u00b5g\/kg dose of ZYNLONTA\u00ae plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 \/PRNewswire\/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA\u00ae (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI\u00ae) in patients with relapsed or refractory (r\/r) diffuse large B-cell lymphoma (r\/r DLBCL). LOTIS-7 trial enrollment is now complete with 100 r\/r DLBCL patients dosed at the selected 150 \u00b5g\/kg dose of ZYNLONTA plus glofitamab. Enrollment occurred in … Continue reading \"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-30T11:23:53+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1614576\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial","datePublished":"2026-06-30T11:23:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/"},"wordCount":1543,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1614576\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/","name":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1614576\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688","datePublished":"2026-06-30T11:23:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1614576\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1614576\/ADC-Therapeutics-SA-logo.jpg?id=OA2744688"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adc-therapeutics-announces-completion-of-enrollment-in-lotis-7-phase-1b-zynlonta-combination-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA\u00ae Combination Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=976955"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/976955\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=976955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=976955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=976955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}